Current immune-checkpoint blockade agents for hepatocellular carcinoma (HCC) treatment mainly consist of anti-PD-1/PD-L1 and anti-CTLA-4 antibodies3-5. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.